Anne B Eldrup from 19A Georges Hill Rd, Newtown, CT 06470, age 58, Phone: 203-364-1981

Us Patents

Methods Of Inhibiting Orthopoxvirus Replication With Nucleoside Compounds
view source
US Patent:

7323453, Jan 29, 2008
Filed:

Feb 7, 2003
Appl. No.:

10/504445
Inventors:

David B. Olsen - Lansdale PA, US
Robert L. LaFemina - Schwenksville PA, US
Anne B. Eldrup - Danbury CT, US
Sanjib Bera - Blacksburg VA, US
Assignee:

Merck & Co., Inc. - Rahway NJ
Isis Pharmaceuticals, Inc. - Carlsbad CA
International Classification:

A01N 43/04
A61K 31/70
C07H 19/00
C07H 19/22
US Classification:

514 48, 514 43, 514 45, 514 46, 514 47
Abstract:

The present invention provides methods of inhibiting orthopoxvirus replication and/or treating orthopoxvirus infection with certain nucleoside compounds and derivatives thereof. These compounds are particularly useful as inhibitors of vaccinia virus and variola virus replication and/or for the treatment of vaccinia virus and variola virus infection. The nucleoside compounds may be administered alone or in combination with other agents active against orthopoxvirus infection, in particular against vaccinia virus or variola virus infection. Another aspect of the present invention provides for the use of such nucleoside compounds in the manufacture of a medicament for the inhibition of orthopoxvirus replication and/or for the treatment of orthopoxvirus infection. Yet a further aspect of the present invention provides such nucleoside compounds for use as a medicament for the inhibition of orthopoxvirus replication and/or for the treatment of orthopoxvirus infection.

C-Purine Nucleoside Analogs As Inhibitors Of Rna-Dependent Rna Viral Polymerase
view source
US Patent:

7534767, May 19, 2009
Filed:

Jun 10, 2005
Appl. No.:

11/628513
Inventors:

Gabor Butora - Martinsville NJ, US
Malcolm MacCoss - Freehold NJ, US
Balkrishen Bhat - Carlsbad CA, US
Anne B. Eldrup - Danbury CT, US
Assignee:

Merck & Co., Inc. - Rahway NJ
International Classification:

A01N 43/04
US Classification:

514 23, 536 292
Abstract:

The present invention provides C-purine nucleoside analogs and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such C-nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the C-nucleoside compounds of the present invention.

2′-Fluoro Substituted Oligomeric Compounds And Compositions For Use In Gene Modulations
view source
US Patent:

7812149, Oct 12, 2010
Filed:

Nov 4, 2003
Appl. No.:

10/700689
Inventors:

Thazha P. Prakash - Carlsbad CA, US
Brenda F. Baker - Carlsbad CA, US
Anne B. Eldrup - Ridgefield CT, US
Muthiah Manoharan - Weston MA, US
Balkrishen Bhat - Carlsbad CA, US
Richard Griffey - Vista CA, US
Eric E. Swayze - Carlsbad CA, US
Stanley T. Crooke - Carlsbad CA, US
Assignee:

Isis Pharmaceuticals, Inc. - Carlsbad CA
International Classification:

C07H 21/04
C07H 21/02
A61K 48/00
US Classification:

536 245, 536 231, 514 44
Abstract:

Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modified sugar and/or backbone modification. In some embodiments the modification is a 2′-F substituent group on a sugar moiety. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleoside of the oligomer has a modified sugar and/or backbone modification.

2′-Substituted Oligomeric Compounds And Compositions For Use In Gene Modulations
view source
US Patent:

7919612, Apr 5, 2011
Filed:

Nov 4, 2003
Appl. No.:

10/701316
Inventors:

Brenda F. Baker - Carlsbad CA, US
Anne B. Eldrup - Ridgefield CT, US
Muthiah Manoharan - Weston MA, US
Balkrishen Bhat - Carlsbad CA, US
Richard Griffey - Vista CA, US
Eric E. Swayze - Carlsbad CA, US
Stanley T. Crooke - Carlsbad CA, US
Thazha P. Prakash - Carlsbad CA, US
Assignee:

Isis Pharmaceuticals, Inc. - Carlsbad CA
International Classification:

C07H 21/04
C07H 21/02
A61K 48/00
US Classification:

536 245, 514 44
Abstract:

Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modified sugar and/or backbone modification. In some embodiments the modification is a 2′ substituent group on a sugar moiety that is not H or OH. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleotide of the oligomer has a modified sugar and/or backbone modification.

Urotensin Ii Receptor Antagonists
view source
US Patent:

8258301, Sep 4, 2012
Filed:

May 12, 2008
Appl. No.:

12/527973
Inventors:

Brian Nicholas Cook - Danbury CT, US
Anne Bettina Eldrup - Danbury CT, US
Ingo Andreas Mugge - New Haven CT, US
Fariba Soleymanzadeh - Danbury CT, US
Sanxing Sun - Danbury CT, US
Yunlong Zhang - Danbury CT, US
Assignee:

Boehringer Ingelheim International GmbH - Ingelheim am Rhein
International Classification:

C07D 471/04
US Classification:

546122, 544362, 544127, 544316, 544331, 540597
Abstract:

Compounds of the formula (I).

Compositions Comprising Alternating 2′-Modified Nucleosides For Use In Gene Modulation
view source
US Patent:

8604183, Dec 10, 2013
Filed:

Nov 4, 2003
Appl. No.:

10/701007
Inventors:

Charles Allerson - Carlsbad CA, US
Balkrishen Bhat - Carlsbad CA, US
Anne B. Eldrup - Ridgefield CT, US
Muthiah Manoharan - Weston MA, US
Richard H. Griffey - Vista CA, US
Brenda F. Baker - Carlsbad CA, US
Eric E. Swayze - Carlsbad CA, US
Assignee:

Isis Pharmaceuticals, Inc. - Carlsbad CA
International Classification:

C07H 21/02
C07H 21/04
C12Q 1/68
C12P 19/34
US Classification:

536 245, 435 6, 435 911, 435 9131, 536 231, 536 243
Abstract:

The present invention provides compositions comprising at least one oligomeric compound comprising an alternating motif and further include a region that is complementary to a nucleic acid target. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In preferred embodiments the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The present invention also provides methods for modulating gene expression.

2'-Methoxy Substituted Oligomeric Compounds And Compositions For Use In Gene Modulations
view source
US Patent:

20040147022, Jul 29, 2004
Filed:

Nov 4, 2003
Appl. No.:

10/701264
Inventors:

Brenda Baker - Carlsbad CA, US
Anne Eldrup - Ridgefield CT, US
Muthiah Manoharan - Weston MA, US
Balkrishen Bhat - Carlsbad CA, US
Richard Griffey - Vista CA, US
Eric Swayze - Carlsbad CA, US
Stanley Crooke - Carlsbad CA, US
International Classification:

C07H021/02
A61K048/00
US Classification:

435/375000, 514/044000, 536/023100
Abstract:

Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modified sugar and/or backbone modification. In some embodiments the modification is a 2′-OCHsubstituent group on a sugar moiety. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleotide of the oligomer has a modified sugar and/or backbone modification.

Chimeric Oligomeric Compounds And Their Use In Gene Modulation
view source
US Patent:

20040147023, Jul 29, 2004
Filed:

Nov 4, 2003
Appl. No.:

10/701265
Inventors:

Brenda Baker - Carlsbad CA, US
Anne Eldrup - Ridgefield CT, US
Muthiah Manoharan - Weston MA, US
Balkrishen Bhat - Carlsbad CA, US
Richard Griffey - Vista CA, US
Eric Swayze - Carlsbad CA, US
Stanley Crooke - Carlsbad CA, US
International Classification:

A61K048/00
C07H021/02
C07H021/04
US Classification:

435/375000, 514/044000, 536/023100
Abstract:

Oligomer compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capble of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes at least one nucleotide comprising a chimeric organic composition. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleotide comprising a chimeric organic composition.